Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.890
-0.150 (-2.98%)
At close: Apr 24, 2026, 4:00 PM EDT
4.930
+0.040 (0.82%)
After-hours: Apr 24, 2026, 7:44 PM EDT
Company Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo.
The company was founded in 2018 and is headquartered in New York, New York.
Nuvation Bio Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 298 |
| CEO | David Hung |
Contact Details
Address: 1500 Broadway, Suite 1401 New York, New York 10036 United States | |
| Phone | 332 208 6102 |
| Website | nuvationbio.com |
Stock Details
| Ticker Symbol | NUVB |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1811063 |
| CUSIP Number | 67080N101 |
| ISIN Number | US67080N1019 |
| Employer ID | 85-0862255 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David T. Hung M.D. | Founder, President, Chief Executive Officer and Chairman |
| Philippe Pierre Sauvage | Chief Financial Officer and Principal Financial Officer |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer |
| Moses Makunje C.P.A. | Vice President of Finance and Principal Accounting and Financial Officer |
| Dr. Stephen Dang Ph.D. | Chief Legal Officer and Corporate Secretary |
| Stacy Markel | Chief People Officer |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer |
| Kerry A. Wentworth | Chief Regulatory Officer |
| Dr. David Liu M.D., Ph.D. | Chief Medical Officer |
| Colleen Sjogren | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2026 | 144 | Filing |
| Apr 17, 2026 | 144 | Filing |
| Apr 10, 2026 | ARS | Filing |
| Apr 10, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 6, 2026 | 144 | Filing |
| Mar 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 2, 2026 | 10-K | Annual Report |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 10, 2026 | 25-NSE | Filing |